Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Gilead Sciences Inc | 204 |
| 2 | Bayer AG | 174 |
| 3 | Dana Farber Cancer Institute Inc | 129 |
| 4 | Bayer Pharma AG | 118 |
| 5 | AstraZeneca AB | 114 |
| 6 | Foundation Medicine Inc | 103 |
| 7 | Boehringer Ingelheim International GmbH | 101 |
| 8 | Kymera Therapeutics Inc | 96 |
| 9 | Institut National de la Santé et de la Recherche Médicale | 91 |
| 10 | F Hoffmann La Roche AG | 87 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 8,381 |
| 2 | A61K | Medicinal preparations | 8,068 |
| 3 | C07D | Heterocyclic compounds | 4,482 |
| 4 | C07K | Peptides | 2,449 |
| 5 | C12N | Microorganisms, enzymes | 972 |
| 6 | C12Q | Measuring/testing involving enzymes | 872 |
| 7 | G01N | Investigating / analysing materials | 799 |
| 8 | C07B | General methods of organic chemistry | 627 |
| 9 | C07F | Organometallic compounds | 519 |
| 10 | Y02A | Climate change adaptation | 390 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB (AZD9291) OR A SALT THEREOF, AND "AZD9291 ANILINE" OR A SALT THEREOF | 2017 | AstraZeneca AB | 11 |
| A kind of Osimertinib preparation method | 2017 | JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. | 7 |
| OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | 2019 | AstraZeneca AB | 4 |
| AN IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB MESYLATE | 2021 | Natco Pharma Ltd | 3 |
| Anticancer compound osimertinib and synthesis method thereof | 2016 | HUANG YANGE | 2 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Lung Cancer Treatments and Mutations | 12 |
| 2 | Cancer Genomics and Diagnostics | 1 |
| 3 | Chemical Synthesis and Analysis | 1 |
| 4 | Chronic Lymphocytic Leukemia Research | 1 |
| 5 | Epigenetics and DNA Methylation | 1 |
| 6 | Extracellular vesicles in disease | 1 |
| 7 | Quinazolinone synthesis and applications | 1 |
| 8 | RNA modifications and cancer | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Suresh S. Ramalingam | Emory University | 27 |
| 2 | Myung‐Ju Ahn | Samsung Medical Center | 24 |
| 3 | James Chih‐Hsin Yang | National Taiwan University Hospital | 21 |
| 4 | Yi‐Long Wu | Guangdong Academy of Medical Sciences | 21 |
| 5 | Byoung Chul Cho | Yonsei University | 19 |
| 6 | Helena A. Yu | Memorial Sloan Kettering Cancer Center | 15 |
| 7 | Pasi A. Jänne | Dana-Farber Cancer Institute | 15 |
| 8 | Terufumi Kato | Kanagawa Prefectural Hospital Organization | 13 |
| 9 | Jia Wang | Shanghai Innovative Research Center of Traditional Chinese Medicine | 6 |
| 10 | Yong He | Daping Hospital | 12 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib | 2004 | 11548 | Lung Cancer Diagnosis and Treatment |
| Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer | 2017 | 5380 | Lung Cancer Diagnosis and Treatment |
| Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer | 2016 | 3359 | Lung Cancer Diagnosis and Treatment |
| Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC | 2019 | 2876 | Lung Cancer Diagnosis and Treatment |
| AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer | 2014 | 2247 | Lung Cancer Treatments and Mutations |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Tagrisso?
Which organizations hold the most patents related to Tagrisso?
What are the main research areas covered in literature on this compound?
What are the most-cited foundational papers on this compound?
How has patent activity for this compound evolved recently?